Initial dual oral combination therapy in pulmonary arterial hypertension

European Respiratory Journal

Volumn 47, Issue 6, 2016, Pages 1727-1736

  Sitbon, Olivier ^a,b,c   Sattler, Caroline ^a,b,c   Bertoletti, Laurent ^d,e   Savale, Laurent ^a,b,c   Cottin, Vincent ^f   Jaïs, Xavier ^a,b,c   De Groote, Pascal ^g   Chaouat, Ari ^h,i   Chabannes, Céline ^j   Bergot, Emmanuel ^k   Bouvaist, Hélène ^l   Dauphin, Claire ^m   Bourdin, Arnaud ⁿ   Bauer, Fabrice ^o   Montani, David ^a,b,c   Humbert, Marc ^a,b,c   Simonneau, Gérald ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d HÔPITAL NORD   (France)

^e University Jean Monnet of Saint Etienne EA3065   (France)

^f UNIVERSITÉ LYON 1   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ UNIVERSITÉ DE LORRAINE   (France)

^j RENNES UNIVERSITY HOSPITAL   (France)

^k CHU CÔTE DE NACRE   (France)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

^m SERVICE DE RHUMATOLOGIE   (France)

ⁿ UNIVERSITY OF MONTPELLIER   (France)

^o UNIVERSITÉ DE ROUEN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; BOSENTAN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; SILDENAFIL; TADALAFIL; AMFEPRAMONE; ANTIHYPERTENSIVE AGENT; PHENYLPROPIONIC ACID DERIVATIVE; PYRIDAZINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DYSPNEA; EXERCISE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OVERALL SURVIVAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL RATE; AGED; COMBINATION DRUG THERAPY; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SAFETY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DIETHYLPROPION; DRUG THERAPY, COMBINATION; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PATIENT SAFETY; PHENYLPROPIONATES; PYRIDAZINES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SILDENAFIL CITRATE; SULFONAMIDES; TADALAFIL; TIME FACTORS; TREATMENT OUTCOME;

EID: 84973495214     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02043-2015     Document Type: Article

References (36)

1. Humbert M. The burden of pulmonary hypertension. Eur Respir J 2007; 30: 1-2.
2. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67-119.
3. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903-975.
4. Rich S. Medical treatment of primary pulmonary hypertension: a bridge to transplantation? Am J Cardiol 1995; 75: 63A-66A.
5. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: D60-D72.
6. Dardi F, Manes A, Palazzini M, et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J 2015; 46: 414-421.
7. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
8. Humbert M, Lau EM, Montani D, et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014; 130: 2189-2208.
9. Ghofrani HA, Humbert M. The role of combination therapy in managing pulmonary arterial hypertension. Eur Respir Rev 2014; 23: 469-475.
10. Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010; 31: 2080-2086.
11. Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012; 186: 790-796.
12. Ogawa A, Ejiri K, Matsubara H. Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 2014; 118: 414-419.
13. Ngian G-S, Stevens W, Prior D, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012; 14: R213.
14. Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 252-260.
15. Manes A, Palazzini M, Leci E, et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 2014; 35: 716-724.
16. Sitbon O, Jaïs X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43: 1691-1697.
17. Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834-844.
18. Humbert M, Sitbon O, Yaici A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
19. Sitbon O, Benza RL, Badesch DB, et al. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J 2015; 46: 152-164.
20. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522-2533.
21. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
22. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
23. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002; 106: 319-324.
24. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39: 589-596.
25. McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D73-D81.
26. Kemp K, Savale L, O'Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 2012; 31: 150-158.
27. Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and tadalafil upfront combination therapy in scleroderma-associated PAH. Am J Respir Crit Care Med 2015; 192: 1102-1110.
28. Rich S. The effects of vasodilators in pulmonary hypertension. Pulmonary vascular or peripheral vascular? Circ Heart Fail 2009; 2: 145-150.
29. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
30. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
31. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359.
32. Bachetti C, Manes A, Dardi F, et al. Comparison between initial combination therapy and initial monotherapy in pulmonary arterial hypertension: a single centre blinded evaluation of patients enrolled in the AMBITION study. Am J Respir Crit Care Med 2015; 191: A4779.
33. Bergot E, Sitbon O, Cottin V, et al. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. Int J Cardiol 2014; 172: 561-567.
34. Kylhammar D, Persson L, Hesselstrand R, et al. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension. Scand Cardiovasc J 2014; 48: 223-233.
35. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
36. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448-456.